Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 16/20 | 0.90 |
| ▸ | CDK4 | P11802 | 8/20 | 0.90 |
| ▸ | CCND1 | P24385 | 8/20 | 0.90 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.66 |
| ▸ | CCND3 | P30281 | 4/20 | 0.64 |
| ▸ | CDK1 | P06493 | 4/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.63 |
| ▸ | CDK2 | P24941 | 4/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.59 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.59 |
| ▸ | CDK9 | P50750 | 2/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.59 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518827 | 1.00 | CDK6 (0.90) | CDK6CDK4CCND1DYRK2CCND3 | |
| Eciruciclib SCHEMBL29518577 | 0.94 | CDK6 (1.00) | CDK6CDK4CCND1DYRK2CCND3 | |
| Eciruciclib SCHEMBL29518576 | 0.94 | CDK6 (1.00) | CDK6CDK4CCND1DYRK2CCND3 | |
| Eciruciclib SCHEMBL17469895 | 0.94 | CDK6 (1.00) | CDK6CDK4CCND1DYRK2CCND3 | |
| Eciruciclib SCHEMBL23145129 | 0.94 | CDK6 (0.98) | CDK6CDK4CCND1DYRK2CCND3 | |
| SCHEMBL21208335 | 0.92 | CDK6 (0.76) | CDK6CDK4CCND1DYRK2CCND3 | |
| SCHEMBL29518571 | 0.92 | CDK6 (0.76) | CDK6CDK4CCND1DYRK2CCND3 | |
| SCHEMBL17469757 | 0.90 | CDK6 (0.73) | CDK6CDK4CCND1DYRK2CCND3 | |
| SCHEMBL29518488 | 0.90 | CDK6 (0.73) | CDK6CDK4CCND1DYRK2CCND3 | |
| SCHEMBL29518408 | 0.89 | CDK6 (0.90) | CDK6CDK4CCND1DYRK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191469-B1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-12-15 | — | — | EP | claimed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | claimed |
| US-20220079944-A1 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | BETA PHARMA, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220079944-A1 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | BETA PHARMA, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3191469-B1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3191469-B1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021061695-A1 | TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS | BETA PHARMA, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10239864-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239864-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239864-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | CDK4, CDK6, CDK2 | CDK6 2/4885CDK4 1/4885CCND1 37/4885 |
| US-20220079944-A1 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | CDK6, CDK4, CDK3 | CDK6 1/4885CDK4 2/4885CCND1 50/4885 |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | CDK4, CDK2, CDK3 | CDK6 4/4885CDK4 1/4885CCND1 41/4885 |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK3, CDK6 | CDK6 3/4885CDK4 1/4885CCND1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.